伏立康唑联合康艾注射液治疗肺癌患者肺部真菌感染的临床观察  

Clinical efficacy of voriconazole combined with Kang′ai injection in treatment of pulmonary fungal infections in lung cancer patients

作　　者：马建忠[1] 汪建英[1] 高天巍[1] 

机构地区：[1]杭州市肿瘤医院ICU,浙江杭州310002

出　　处：《中华医院感染学杂志》2014年第4期866-868,共3页Chinese Journal of Nosocomiology

基　　金：杭州市卫生科技计划基金资助项目(2013A33)

摘　　要：目的分析比较伏立康唑联合康艾注射液治疗肺癌患者合并肺部真菌感染的临床效果,对康艾注射液治疗肺癌合并肺部真菌感染的安全性和有效性进行评价。方法回顾性分析2011年7月-2013年7月医院收治的肺癌合并院内肺部真菌感染患者82例,按照治疗方式的不同分为观察组41例(康艾注射液联合伏立康唑治疗)和对照组41例(伏立康唑治疗),比较两组体温和白细胞恢复正常时间、住院时间、机体功能状态及临床总体疗效,使用SPSS 16.0软件统计分析。结果观察组体温恢复时间(3.5±1.8)d、住院时间(15.3±3.4)d、机体功能状态改善有效率为51.2%、临床总有效率56.1%,对照组分别是(5.6±2.5)d、(19.8±4.5)d、37.1%和36.6%,两组比较差异有统计学意义(P<0.05),观察组白细胞计数恢复正常范围的天数与对照组差异无统计学意义。结论康艾注射液联合伏立康唑对肺癌合并院内肺部真菌感染患者是一种有效的治疗方式,能够改善机体功能、提高疗效、促进恢复,值得临床推广借鉴。OBJECTIVE To observe the clinical efficacy of voriconazole combined with Kangrai injection in treatment of lung cancer complicated with pulmonary fungal infections and evaluate the safety and effectiveness of Kang^ai injection in treatment of lung cancer complicated with pulmonary fungal infections. METHODS Totally 82 lung cancer patients complicated with pulmonary fungal infections, who were treated in the hospital from Jul 2011 to Jul 2013, were retrospectively analyzed, the subjects were divided into the observation group with 41 cases （Kang^ai injection combined with voriconazole） and the control group with 41 cases （voriconazole）, then the body temperature, recovery time of white blood cells, hospitalization duration, body function, and total clinical efficacy were compared between the two groups, and the statistical analysis was performed with the use of SPSS16. 0 software. RESULTS The recovery time of body temperature was （3.5 --4- 1.8） days in the observation group, （5.6 2.5）days in the control group; the hospitalization duration was （15.3 ~ 3.4） days in the observation group, （19.8~4.5） days in the control group; the effective rate of improvement of body function was 51. 2~ in the observation group, 37. 1~ in the control group; the total effective rate was 56. 1~ in the observation group, 36.6~ in the control group, as compared with the control group, the differences were statistically significant（P~ 0.05）; the difference in the duration of the WBC counts＇ returning to a normal range between the observation group and the control group was not statistically significant. CONCLUSION Kang＇ai injection combined with voriconazole can improve body function, improve efficacy, and promote the recovery, which is a reliable and effective treatment method for the lung cancer patients complicated with pulmonary fungaI infections and is worthy to be promoted in the hospital.

关 键 词：康艾注射液 伏立康唑 肺癌 真菌感染 

分 类 号：R978.1[医药卫生—药品]